AIDS, HIV Infections
Conditions
Keywords
Gag, vaccine, adjuvant, HIV, Pol, Nef
Brief summary
GSK has constructed a new HIV immunogen comprised of conserved parts of the HIV virus (gag, pol and nef). The principal objectives of this study are to evaluate the reactogenicity and safety of this candidate vaccine with or without a GSK proprietary adjuvant system at three different doses and to evaluate the CD4+ T-cell response in terms of proportion of responders to the antigens two weeks after the second vaccination.
Detailed description
This is a single center, observer-blind, randomized, dose-escalating, staggered study with 6 groups: 3 groups of 50 subjects receiving the adjuvanted candidate vaccine, at 3 different doses and 3 groups of 10 subjects receiving the non-adjuvanted candidate vaccine in water for injection, at 3 different doses. The vaccination schedule will be 0-1 month. Blood samples will be collected at 8 visits. The duration of the study will be approximately 14 months for each subject. Rationale for Protocol Posting Amendment: The third vaccination will be cancelled and the visit at Month 7 will be postponed to Month 9. The Protocol Posting has also been updated in order to comply with the FDA Amendment Act, Sep 2007.
Interventions
BIOLOGICALHIV vaccine 732461
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* A male or female between and including 18-40 years at the time of first vaccination. * Written informed consent obtained from the subject prior to any study procedure. * Subjects who the investigator believes that they can and will comply with the requirements of the protocol. * Good general health without significant medical history, physical examination findings, or clinically significant abnormal laboratory results. * If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series. * Negative for antibodies against HIV-1, HIV-2 and negative for HIV p24 antigen within 56 days (8 weeks) prior to enrolment. Subjects must be willing to accept HIV test results. Individuals who elect not to receive test results will not be enrolled. * Negative for anti-HBc Ab, HBsAg and anti-HCV Ab.
Exclusion criteria
* Women who are pregnant or breast-feeding. * Subjects with a history of, or current, alcohol or substance abuse. * The subject is at high risk of acquiring HIV according to the behavioural risk assessment questionnaire. * Morbid obesity * Previous inclusion in a HIV vaccines trial. * Receipt of live attenuated vaccines within 30 days of enrolment. * Receipt of medically indicated subunit or killed vaccines or allergy treatment with antigen injections within 14 days of study vaccine administration. * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Prior receipt of HIV-1 vaccines or placebo in a previous HIV vaccine trial. * Receipt of blood products 120 days prior to HIV screening. * Receipt of immunoglobulin 120 days prior to HIV screening. * History of serious adverse reactions including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema and abdominal pain to vaccines. * History of serious allergic reaction to any substance requiring hospitalization or emergency medical care. * History of immunodeficiency or autoimmune disease. * History of malignancy (unless there has been surgical excision followed by a sufficient observation period, of at least 5 years, to give a reasonable assurance of sustained cure and which, in the estimate of the investigator, is not likely to recur during the study period). * Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccination. * History of type I or type II diabetes mellitus including cases controlled with diet alone. A subject with past gestational diabetes is eligible. * Thyroid disease including history of thyroidectomy and diagnoses requiring medication. A subject not requiring thyroid medicine within the past 12 months is eligible. * Acute disease at the time of enrolment. * Asthma requiring daily steroid or long acting β agonist prevention. * Unstable asthma. * Food- or wine-induced asthma. * Known sensitivity to sulfites or aspirin. * Bleeding disorder that was diagnosed by a physician. A subject who states that he or she has easy bruising or bleeding, but does not carry a formal diagnosis and has intramuscular (IM) injections and blood draws without any adverse experience is eligible. * History of any serious neurologic disorder or seizure * History of major congenital defect * History of chronic fatigue syndrome or fibromyalgia * Splenectomy * Hypertension. A subject with hypertension is eligible if he or she is controlled on medication and the documented blood pressure is less than 150/100. * Any medical, psychiatric or social condition, or occupational or other responsibility that, in the judgement of the investigator, would interfere with or serve as a contradiction to adherence to the study protocol or ability to give informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects With Any and Grade 3 Solicited Local Symptoms | During the 7-day (Days 0-6) follow-up period after each vaccination and overall (across doses) | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. |
| Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | During the 7-day (Days 0-6) follow-up period after each vaccination and overall (across doses) | Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, sweating, gastrointestinal symptoms(nausea, vomiting, diarrhea, and/or abdominal pain). Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. |
| Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | During the 30-day (Days 0-29) follow-up period after vaccination (across doses) | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. |
| Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | During the whole study period (From Month 0 up to Month 12) | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | At Month 0 | The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\]. |
| Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | At Month 1 | The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\]. |
| Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | At Day 44 | The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\]. |
| Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | At Month 2 | The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[RBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\]. |
| Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | At Month 6 | The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\]. |
| Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | At Month 9 | The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\]. |
| Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | At Month 12 | The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\]. |
| Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At Day 44 | Antigen-specific CD4+ T-cells can express cluster of differentiation 40-ligand (CD40-L) and produce the cytokines Interleukin 2 (IL-2) and/or Tumor Necrosis Factor alpha (TNF-α) and/or Interferon-gamma (IFN-γ). The frequency of antigen specific CD4+T-cells was calculated as the difference between the frequency of CD4+T-cells producing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L), upon in vitro stimulation with the peptide pools derived from the antigen minus the frequency of CD4+T-cells producing at least 2 cytokines upon in vitro stimulation in medium only.A responder was a subject with an antigen-stimulated CD4+T cells response greater than or equal to the cut-off value. The same cut-off value was used for all subjects and all antigen responses post-vaccination. It was calculated from the pre-vaccination CD4+T cell responses (the frequency of antigen-stimulated CD4+T cells expressing at least two markers; i.e. all doubles) for all subjects. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | At Month 0, Day 44, Month 2, Month 6 and Month 12 | Antigen-specific CD4+ T-cells can express CD40 ligand (CD40-L) and produce the cytokines Interleukin 2 (IL-2) and/or Tumor Necrosis Factor alpha (TNF-α) and/or Interferon-gamma (IFN-γ). Frequency of CD4+ T-cells expressing markers in response to the F4co fusion protein (all antigens) was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (p17, p24, Nef, RT). Results are presented as determined by Intracellular Cytokine Staining (ICS). |
| Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | At Month 0, Day 44, Month 2, Month 6 and Month 12 | Antigen-specific CD4+ T-cells can express CD40 ligand (CD40-L) and produce the cytokines Interleukin 2 (IL-2) and/or Tumor Necrosis Factor alpha (TNF-α) and/or Interferon-gamma (IFN-γ). Frequency of CD4+ T-cells expressing markers in response to the F4co fusion protein (all antigens) was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (p17, p24, Nef, RT). Results are presented as determined by Intracellular Cytokine Staining (ICS). |
| Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | At Month 0, Day 44, Month 2, Month 6 and Month 12 | Anti-p17, -p24, -Nef, -RT and -F4co antibody titers were measured by Enzyme Linked Immunosorbent Assay (ELISA) and presented as geometric mean titers (GMTs). |
Countries
Belgium
Participant flow
Pre-assignment details
A total of 229 subjects were enrolled and screened in this study, and 49 of these were excluded before vaccination.
Participants by arm
| Arm | Count |
|---|---|
| SB732461 Non-adjuvanted_LD Group Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted low-antigen dose \[LD\] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30. | 10 |
| SB732461 Non-adjuvanted_MD Group Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted medium-antigen dose \[MD\] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30. | 10 |
| SB732461 Non-adjuvanted_HD Group Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted high-antigen dose \[HD\] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30. | 10 |
| SB732461 adjuvanted_LD Group Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted low-antigen dose \[LD\] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30. | 50 |
| SB732461 adjuvanted_MD Group Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted medium-antigen dose \[MD\] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30. | 50 |
| SB732461 adjuvanted_HD Group Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted high-antigen dose \[HD\] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30. | 50 |
| Total | 180 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Migrated/moved from study area | 0 | 0 | 0 | 1 | 1 | 1 |
| Overall Study | Other | 0 | 1 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | SB732461 Non-adjuvanted_LD Group | SB732461 Non-adjuvanted_MD Group | SB732461 Non-adjuvanted_HD Group | SB732461 adjuvanted_LD Group | SB732461 adjuvanted_MD Group | SB732461 adjuvanted_HD Group | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 21.4 Years STANDARD_DEVIATION 3.75 | 21.8 Years STANDARD_DEVIATION 3.19 | 22.5 Years STANDARD_DEVIATION 4.99 | 22.0 Years STANDARD_DEVIATION 5.04 | 22.2 Years STANDARD_DEVIATION 3.66 | 22.9 Years STANDARD_DEVIATION 5.43 | 22.3 Years STANDARD_DEVIATION 4.62 |
| Race/Ethnicity, Customized Other - Unspecified | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 4 Participants |
| Race/Ethnicity, Customized White - Arabic/North African heritage | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized White - Caucasian/European heritage | 7 Participants | 10 Participants | 10 Participants | 50 Participants | 47 Participants | 50 Participants | 174 Participants |
| Sex: Female, Male Female | 7 Participants | 7 Participants | 7 Participants | 33 Participants | 28 Participants | 32 Participants | 114 Participants |
| Sex: Female, Male Male | 3 Participants | 3 Participants | 3 Participants | 17 Participants | 22 Participants | 18 Participants | 66 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 10 | 0 / 10 | 0 / 10 | 0 / 50 | 0 / 50 | 0 / 50 |
| other Total, other adverse events | 8 / 10 | 7 / 10 | 9 / 10 | 50 / 50 | 50 / 50 | 50 / 50 |
| serious Total, serious adverse events | 0 / 10 | 0 / 10 | 0 / 10 | 2 / 50 | 2 / 50 | 2 / 50 |
Outcome results
Primary
Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44
The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].
Time frame: At Day 44
Population: The analysis was preformed on the Total Vaccinated cohort, which included vaccinated subjects with at least one vaccine administration documented for whom data were available and who had their symptom sheets filled in.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Above | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Within | 8 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Within | 6 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Above | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Above | 3 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Within | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Above | 4 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Above | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Within | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Above | 6 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Within | 44 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Within | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Within | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Within | 7 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Above | 3 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Within | 10 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Below | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Within | 46 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Below | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Above | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Within | 47 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Below | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Within | 46 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Above | 4 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Below | 4 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Within | 47 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Above | 8 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Within | 42 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Above | 4 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Below | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Below | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Above | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Within | 6 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Below | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Above | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Within | 43 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Below | 4 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Below | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Within | 44 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Creatinine | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | WBC | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Urea Nitrogen | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Within | 46 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Within | 46 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Neutrophils | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Basophils | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Below | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Potassium | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Within | 34 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Within | 45 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Within | 46 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Lymphocytes | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Below | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Monocytes | Above | 12 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Sodium | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Eosinophils | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | ALT | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | Haemoglobin | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | AST | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44 | RBC | Above | 0 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0
The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].
Time frame: At Month 0
Population: The analysis was performed on the Total Vaccinated cohort, which included vaccinated subjects with at least one vaccine administration documented for whom data were available and who had their symptom sheets filled in.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Above | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Above | 3 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Within | 7 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Above | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Below | 4 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Below | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Below | 6 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Within | 40 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Above | 7 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Within | 44 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Above | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Within | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Within | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Below | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Within | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Within | 43 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Within | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Above | 5 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Within | 48 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Within | 7 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Above | 3 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Below | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Within | 46 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Within | 46 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Above | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Within | 45 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Below | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Above | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Above | 10 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Within | 40 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Below | 4 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Below | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Above | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Above | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Within | 7 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Above | 3 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Below | 6 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Within | 50 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Sodium | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Platelets | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Within | 50 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Basophils | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Eosinophils | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Above | 11 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Within | 39 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Monocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Below | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Above | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Hematocrit | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | AST | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Within | 50 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Lymphocytes | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Below | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Neutrophils | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Creatinine | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | WBC | Within | 44 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | RBC | Below | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Within | 50 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0 | Potassium | Below | 0 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1
The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].
Time frame: At Month 1
Population: The analysis was preformed on the Total Vaccinated cohort, which included vaccinated subjects with at least one vaccine administration documented for whom data were available and who had their symptom sheets filled in.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Above | 3 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Above | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Within | 7 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Within | 38 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Within | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Above | 11 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Within | 44 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Above | 6 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Within | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Within | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Within | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Below | 4 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Within | 6 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Above | 4 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Within | 44 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Within | 47 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Above | 6 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Within | 47 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Above | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Above | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Within | 39 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Below | 5 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Below | 7 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Within | 44 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Above | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Above | 11 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Within | 42 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Above | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Above | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Within | 5 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Above | 5 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Below | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Within | 50 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Within | 50 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Above | 19 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Above | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Above | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Within | 43 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Below | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Above | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Above | 4 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Within | 50 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Below | 4 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Below | 4 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | AST | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Within | 45 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Within | 31 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Above | 5 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Potassium | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Neutrophils | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Monocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Hematocrit | Within | 50 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Eosinophils | Above | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Haemoglobin | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Lymphocytes | Within | 43 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Platelets | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Sodium | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | RBC | Unknown | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | WBC | Within | 45 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1 | Urea Nitrogen | Above | 1 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12
The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].
Time frame: At Month 12
Population: The analysis was preformed on the Total Vaccinated cohort, which included vaccinated subjects with at least one vaccination administration documented for whom data were available and who had their symptom sheets filled in.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Below | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Whitin | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Whitin | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Whitin | 8 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Whitin | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Above | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Whitin | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Whitin | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Whitin | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Whitin | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Whitin | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Whitin | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Whitin | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Whitin | 8 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Whitin | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Above | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Whitin | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Whitin | 8 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Whitin | 10 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Whitin | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Whitin | 45 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Above | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Whitin | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Whitin | 45 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Whitin | 41 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Above | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Above | 4 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Whitin | 45 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Above | 4 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Whitin | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Whitin | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Above | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Whitin | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Whitin | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Whitin | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Below | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Whitin | 43 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Above | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Whitin | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Below | 5 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Whitin | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Above | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Whitin | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Whitin | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Whitin | 6 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Above | 3 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Whitin | 8 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Whitin | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Whitin | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Whitin | 7 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Whitin | 8 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Whitin | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Whitin | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Whitin | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Whitin | 8 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Above | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Whitin | 7 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Whitin | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Whitin | 8 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Whitin | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Whitin | 8 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Whitin | 9 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Whitin | 44 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Whitin | 47 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Whitin | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Whitin | 43 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Above | 6 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Above | 10 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Whitin | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Whitin | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Below | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Whitin | 42 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Whitin | 47 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Above | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Whitin | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Below | 7 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Whitin | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Whitin | 46 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Whitin | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Whitin | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Below | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Above | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Whitin | 38 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Above | 5 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Whitin | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Whitin | 46 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Whitin | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Whitin | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Whitin | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Above | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Whitin | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Whitin | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Whitin | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Whitin | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Whitin | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Whitin | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Above | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Whitin | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Whitin | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Whitin | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Above | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Whitin | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Whitin | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Whitin | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Whitin | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Above | 8 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Whitin | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Hematocrit | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Whitin | 41 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Whitin | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Whitin | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Above | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Urea Nitrogen | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Whitin | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Monocytes | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Whitin | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Platelets | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Above | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Whitin | 45 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Below | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Whitin | 43 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Lymphocytes | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Whitin | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Whitin | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Whitin | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | RBC | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Whitin | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Eosinophils | Above | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Potassium | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Whitin | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Haemoglobin | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Whitin | 46 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Sodium | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Whitin | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Neutrophils | Below | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | AST | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | WBC | Below | 6 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Basophils | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Whitin | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12 | Creatinine | Unknown | 1 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2
The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[RBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].
Time frame: At Month 2
Population: The analysis was preformed on the Total Vaccinated cohort, which included vaccinated subjects with at least one vaccine administration documented for whom data were available and who had their symptom sheets filled in.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Within | 7 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Below | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Above | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Above | 3 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Above | 4 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Within | 8 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Within | 6 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Below | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Within | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Within | 45 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Below | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Above | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Within | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Above | 7 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Within | 50 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Below | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Within | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Within | 43 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Within | 48 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Within | 5 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Above | 5 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Within | 10 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Below | 5 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Within | 47 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Within | 37 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Below | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Above | 12 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Within | 43 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Within | 41 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Above | 8 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Within | 45 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Below | 4 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Within | 43 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Unknown | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Above | 5 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Above | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Unknown | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Within | 10 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Basophils | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Within | 46 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Above | 16 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Within | 33 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Monocytes | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Urea Nitrogen | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Above | 4 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Within | 42 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Below | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Eosinophils | Above | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Above | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Within | 42 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Below | 5 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Neutrophils | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Within | 43 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Lymphocytes | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Hematocrit | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | WBC | Below | 5 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Haemoglobin | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | RBC | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | AST | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Sodium | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Creatinine | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Platelets | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2 | Potassium | Above | 0 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6
The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].
Time frame: At Month 6
Population: The analysis was preformed on the Total Vaccinated cohort, which included vaccinated subjects with at least one vaccine administration documented for whom data were available and who had their symptom sheets filled in.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Within | 8 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Above | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Above | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Unknwon | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Above | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Within | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Within | 41 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Within | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Above | 8 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Within | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Within | 49 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Above | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Within | 8 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Within | 7 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Within | 8 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Within | 8 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Within | 8 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Within | 8 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Unknwon | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Within | 42 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Below | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Within | 47 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Above | 7 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Above | 15 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Within | 34 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Within | 47 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Below | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Within | 43 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Below | 6 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Unknwon | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Above | 5 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Below | 7 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Within | 44 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Within | 42 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Above | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Within | 7 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Within | 6 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Below | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Within | 7 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Unknwon | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Unknwon | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Above | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Within | 46 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Creatinine | Unknwon | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Within | 46 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Below | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Hematocrit | Unknwon | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Urea Nitrogen | Unknwon | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Above | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Unknwon | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Within | 45 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Below | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Platelets | Unknwon | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Above | 4 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Within | 42 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Within | 44 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Lymphocytes | Unknwon | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Above | 18 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | RBC | Unknwon | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Unknwon | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Eosinophils | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Within | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Sodium | Unknwon | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Within | 30 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Monocytes | Unknwon | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Unknwon | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Unknwon | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Within | 44 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Below | 4 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Unknwon | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | WBC | Below | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | ALT | Unknwon | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Potassium | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | Basophils | Unknwon | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6 | AST | Within | 49 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9
The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].
Time frame: At Month 9
Population: The analysis was preformed on the Total Vaccinated cohort, which included vaccinated subjects with at least one vaccine administration documented for whom data were available and who had their symptom sheets filled in.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Above | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Within | 8 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Above | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Within | 8 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Above | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Below | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Below | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Above | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Below | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Within | 8 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Within | 9 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Within | 10 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Within | 9 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Within | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Below | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Within | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Above | 4 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Above | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Above | 17 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Below | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Below | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Within | 45 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Below | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Within | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Above | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Within | 46 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Within | 47 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Within | 49 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Within | 48 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Above | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Within | 32 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Unknown | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Within | 46 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Within | 8 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Above | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Above | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Below | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Within | 9 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Below | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Within | 10 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Unknown | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Above | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Within | 38 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Above | 11 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Within | 48 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Above | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Below | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Within | 47 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Above | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Below | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Within | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Below | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Within | 46 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Above | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Within | 50 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Within | 46 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Above | 4 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Unknown | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Below | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Within | 47 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Above | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Above | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Within | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Above | 3 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Within | 6 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Unknown | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Within | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Below | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Unknown | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Within | 46 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Within | 45 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Above | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Within | 35 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Below | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Within | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Below | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Urea Nitrogen | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Within | 45 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Platelets | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Above | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | ALT | Above | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Within | 45 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Within | 44 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Within | 46 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | AST | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Below | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Above | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Below | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Lymphocytes | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Above | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Within | 43 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Within | 47 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Within | 46 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Eosinophils | Below | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | WBC | Below | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Sodium | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Neutrophils | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Below | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Creatinine | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | RBC | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Haemoglobin | Within | 45 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Monocytes | Above | 13 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Basophils | Unknown | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Hematocrit | Above | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9 | Potassium | Above | 0 Participants |
Primary
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) follow-up period after each vaccination and overall (across doses)
Population: The analysis was performed on the Total Vaccinated Cohort, which included vaccinated subjects with at least one vaccine administration documented for whom data were available and who had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Overall | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Overall | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Overall | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Overall | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Overall | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Overall | 3 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 3 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Overall | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 4 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Overall | 5 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Overall | 6 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 4 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 5 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 9 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 47 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 14 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 5 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 11 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 4 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Overall | 7 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Overall | 14 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Overall | 7 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 5 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 6 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Overall | 49 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Overall | 13 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Overall | 13 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Overall | 23 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 12 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Overall | 5 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Overall | 18 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 4 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 13 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 11 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Overall | 50 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 17 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 49 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 1 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 49 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Overall | 3 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 18 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Overall | 12 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Overall | 25 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 25 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 49 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 5 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Overall | 10 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Overall | 4 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Overall | 50 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 4 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 48 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 17 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Overall | 19 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 9 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 6 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 10 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, sweating, gastrointestinal symptoms(nausea, vomiting, diarrhea, and/or abdominal pain). Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) follow-up period after each vaccination and overall (across doses)
Population: The analysis was performed on the Total Vaccinated Cohort, which included vaccinated subjects with at least one vaccine administration documented for whom data were available and who had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Overall | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Overall | 5 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 3 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Overall | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Overall | 4 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Overall | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Overall | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Overall | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 3 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Overall | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Overall | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Overall | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Overall | 5 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Overall | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Overall | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Dose 1 | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 3 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Overall | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Overall | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Dose 1 | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Overall | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Overall | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 2 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Overall | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Overall | 3 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Overall | 4 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Overall | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Overall | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Overall | 5 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 5 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 4 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Overall | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Overall | 4 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Overall | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Dose 1 | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Overall | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 4 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Overall | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Overall | 6 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Dose 2 | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Overall | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Overall | 5 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Dose 2 | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Overall | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Overall | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 3 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Overall | 3 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Dose 1 | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 3 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Dose 1 | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 5 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Overall | 3 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Overall | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 4 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 3 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Overall | 4 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 2 | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Overall | 5 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Overall | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 1 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 13 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 24 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 5 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 29 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 13 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Overall | 10 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Overall | 5 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Dose 1 | 8 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Dose 2 | 20 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 27 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 29 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 1 | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Overall | 31 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 2 | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 7 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Dose 1 | 9 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 26 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Overall | 23 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 38 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Overall | 27 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Overall | 42 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Overall | 28 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 8 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Overall | 22 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 26 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Overall | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Overall | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 28 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 37 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Overall | 40 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Overall | 3 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Overall | 30 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Dose 2 | 19 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 9 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Overall | 40 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 31 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 39 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 39 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 31 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 6 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 20 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Overall | 30 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Overall | 40 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Overall | 31 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Overall | 11 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 3 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 28 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Dose 1 | 9 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 8 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Dose 2 | 12 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Overall | 47 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 24 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 3 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 3 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 1 | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Dose 1 | 6 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 21 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 19 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 20 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 19 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 6 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 43 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 7 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 43 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 29 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 29 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Dose 2 | 15 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 2 | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 37 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 5 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 37 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 31 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 6 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 31 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 24 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 24 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Overall | 7 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Overall | 46 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Overall | 29 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Overall | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Overall | 29 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Overall | 21 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Overall | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Overall | 16 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Overall | 42 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Overall | 5 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Overall | 42 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Overall | 35 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Overall | 6 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Overall | 35 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Overall | 27 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Overall | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Overall | 27 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Overall | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 28 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Overall | 46 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 37 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 6 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 37 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 28 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Overall | 41 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Dose 2 | 11 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 2 | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Dose 2 | 13 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 25 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Overall | 26 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Overall | 8 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 25 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 44 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 44 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Overall | 4 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Overall | 41 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 10 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 11 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 21 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 4 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 11 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Overall | 36 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 23 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 21 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 24 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Dose 1 | 5 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Overall | 8 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 1 | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Dose 1 | 8 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Overall | 35 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 3 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 32 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Overall | 1 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 33 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Overall | 26 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Overall | 26 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Overall | 46 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Overall | 12 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 23 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Overall | 26 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal, Overall | 17 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 4 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 23 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 7 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal, Overall | 13 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During the 30-day (Days 0-29) follow-up period after vaccination (across doses)
Population: The analysis was performed on the Total Vaccinated Cohort, which included vaccinated subjects with at least one vaccine administration documented for whom data were available and who had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AE(s) | 5 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AE(s) | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AE(s) | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AE(s) | 6 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AE(s) | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AE(s) | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AE(s) | 7 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AE(s) | 1 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AE(s) | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AE(s) | 9 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AE(s) | 42 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AE(s) | 22 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AE(s) | 5 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AE(s) | 15 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AE(s) | 30 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AE(s) | 15 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AE(s) | 6 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AE(s) | 33 Participants |
Primary
Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens
Antigen-specific CD4+ T-cells can express cluster of differentiation 40-ligand (CD40-L) and produce the cytokines Interleukin 2 (IL-2) and/or Tumor Necrosis Factor alpha (TNF-α) and/or Interferon-gamma (IFN-γ). The frequency of antigen specific CD4+T-cells was calculated as the difference between the frequency of CD4+T-cells producing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L), upon in vitro stimulation with the peptide pools derived from the antigen minus the frequency of CD4+T-cells producing at least 2 cytokines upon in vitro stimulation in medium only.A responder was a subject with an antigen-stimulated CD4+T cells response greater than or equal to the cut-off value. The same cut-off value was used for all subjects and all antigen responses post-vaccination. It was calculated from the pre-vaccination CD4+T cell responses (the frequency of antigen-stimulated CD4+T cells expressing at least two markers; i.e. all doubles) for all subjects.
Time frame: At Day 44
Population: Analysis was performed on the According-to-Protocol cohort for Immunogenicity that included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with procedures and intervals defined in protocol, with no elimination criteria during study) for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 1 antigen | 1 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 2 antigens | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 3 antigens | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | All 4 antigens | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 3 antigens | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 2 antigens | 1 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 1 antigen | 2 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | All 4 antigens | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | All 4 antigens | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 3 antigens | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 2 antigens | 2 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 1 antigen | 2 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 1 antigen | 46 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | All 4 antigens | 37 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 2 antigens | 46 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 3 antigens | 46 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 3 antigens | 34 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | All 4 antigens | 22 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 2 antigens | 38 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 1 antigen | 40 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 2 antigens | 34 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 3 antigens | 31 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | All 4 antigens | 23 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens | At least 1 antigen | 35 Participants |
Primary
Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the whole study period (From Month 0 up to Month 12)
Population: The analysis was performed on the Total Vaccinated Cohort, which included vaccinated subjects with at least one vaccine administration documented for whom data were available and who had their symptom sheets filled in.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | SAEs | SAEs | 0 Participants |
| SB732461 Non-adjuvanted_LD Group | Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | Related SAEs | SAEs | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | SAEs | SAEs | 0 Participants |
| SB732461 Non-adjuvanted_MD Group | Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | Related SAEs | SAEs | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | SAEs | SAEs | 0 Participants |
| SB732461 Non-adjuvanted_HD Group | Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | Related SAEs | SAEs | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | Related SAEs | SAEs | 0 Participants |
| SB732461 adjuvanted_LD Group | Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | SAEs | SAEs | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | SAEs | SAEs | 2 Participants |
| SB732461 adjuvanted_MD Group | Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | Related SAEs | SAEs | 0 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | SAEs | SAEs | 2 Participants |
| SB732461 adjuvanted_HD Group | Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs | Related SAEs | SAEs | 0 Participants |
Secondary
Antibody Titers Against p17, p24, Nef, RT and F4co Antigens
Anti-p17, -p24, -Nef, -RT and -F4co antibody titers were measured by Enzyme Linked Immunosorbent Assay (ELISA) and presented as geometric mean titers (GMTs).
Time frame: At Month 0, Day 44, Month 2, Month 6 and Month 12
Population: Analysis was performed on the According-to-Protocol cohort for Immunogenicity that included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with procedures and intervals defined in protocol, with no elimination criteria during study) for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Day 0 | 116.0 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Day 44 | 93.5 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 2 | 152.1 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 12 | 59.5 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 12 | 74.3 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 2 | 26.1 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 6 | 59.5 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Day 44 | 157.8 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 0 | 21.0 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 6 | 93.5 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Day 44 | 62.5 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Day 0 | 62.5 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Day 44 | 23.8 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 12 | 25.1 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 12 | 93.5 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 2 | 76.7 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 2 | 93.5 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Day 0 | 59.5 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 6 | 71.4 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 12 | 135.9 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Day 44 | 65.3 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 2 | 69.7 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 6 | 144.9 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Day 0 | 93.5 Titers |
| SB732461 Non-adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 6 | 22.9 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 2 | 97.5 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 6 | 59.5 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 0 | 24.6 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 2 | 185.3 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Day 44 | 120.3 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 12 | 93.5 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 2 | 85.6 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 12 | 59.5 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Day 44 | 42.1 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 6 | 135.4 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Day 44 | 133.3 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 12 | 62.5 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 12 | 154.2 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Day 0 | 138.0 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Day 44 | 95.5 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 2 | 107.6 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Day 0 | 62.5 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 2 | 34.7 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 12 | 23.6 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Day 0 | 64.7 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 6 | 25.5 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 6 | 93.5 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Day 0 | 109.5 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Day 44 | 229.2 Titers |
| SB732461 Non-adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 6 | 75.7 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Day 0 | 93.5 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 2 | 96.5 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 0 | 21.0 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 6 | 62.5 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 12 | 72.0 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 6 | 93.5 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 2 | 93.5 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 12 | 93.5 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Day 0 | 59.5 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 6 | 31.0 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Day 44 | 88.8 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Day 44 | 184.6 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 2 | 87.4 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 6 | 83.0 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 12 | 70.8 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 2 | 31.5 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Day 0 | 116.0 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Day 44 | 104.2 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 2 | 168.4 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 6 | 173.8 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 12 | 33.1 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Day 44 | 42.7 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 12 | 116.0 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Day 0 | 69.1 Titers |
| SB732461 Non-adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Day 44 | 100.1 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 2 | 12467.6 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 12 | 790.7 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Day 44 | 7027.2 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 2 | 12453.4 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Day 44 | 18765.3 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 6 | 705.5 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 6 | 2133.7 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 2 | 553.2 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 2 | 5761.6 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Day 0 | 59.5 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 6 | 1303.1 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 0 | 21.0 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 12 | 1032.4 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Day 0 | 93.5 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 12 | 128.0 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 6 | 169.0 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 12 | 462.1 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Day 44 | 8979.1 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Day 0 | 120.0 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Day 44 | 27263.0 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Day 44 | 824.9 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 12 | 1254.8 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 2 | 4770.3 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 6 | 2800.2 Titers |
| SB732461 adjuvanted_LD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Day 0 | 62.5 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Day 0 | 59.5 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Day 0 | 93.5 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Day 44 | 1416.4 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 2 | 808.2 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 6 | 167.4 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 12 | 140.5 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Day 44 | 18788.8 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 2 | 11238.4 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 6 | 1898.0 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 12 | 840.6 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Day 0 | 129.6 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Day 44 | 20504.6 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 2 | 12378.1 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 6 | 1617.1 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 12 | 710.4 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Day 0 | 64.2 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Day 44 | 10019.9 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 2 | 6543.3 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 6 | 902.5 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 12 | 428.7 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 0 | 21.0 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Day 44 | 11151.6 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 2 | 4607.8 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 6 | 1081.4 Titers |
| SB732461 adjuvanted_MD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 12 | 1154.0 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 0 | 21.5 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Day 0 | 62.5 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 12 | 1330.2 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 6 | 2712.2 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Month 2 | 17926.2 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Day 44 | 1499.7 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Day 44 | 12359.6 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Day 44 | 26844.9 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-Nef, Day 0 | 136.1 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 12 | 762.6 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 6 | 2082.9 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Day 0 | 96.3 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 2 | 5438.7 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Month 2 | 12541.9 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Day 44 | 21089.3 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p24, Day 0 | 62.1 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 12 | 133.7 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 12 | 837.5 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-F4co, Month 6 | 1081.4 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 6 | 146.6 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 12 | 471.1 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 6 | 883.9 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Month 2 | 6959.8 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-RT, Day 44 | 11812.0 Titers |
| SB732461 adjuvanted_HD Group | Antibody Titers Against p17, p24, Nef, RT and F4co Antigens | Anti-p17, Month 2 | 1189.3 Titers |
Secondary
Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers
Antigen-specific CD4+ T-cells can express CD40 ligand (CD40-L) and produce the cytokines Interleukin 2 (IL-2) and/or Tumor Necrosis Factor alpha (TNF-α) and/or Interferon-gamma (IFN-γ). Frequency of CD4+ T-cells expressing markers in response to the F4co fusion protein (all antigens) was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (p17, p24, Nef, RT). Results are presented as determined by Intracellular Cytokine Staining (ICS).
Time frame: At Month 0, Day 44, Month 2, Month 6 and Month 12
Population: Analysis was performed on the According-to-Protocol cohort for Immunogenicity that included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with procedures and intervals defined in protocol, with no elimination criteria during study) for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Day 44 | 59.75 CD4+ T-cells/million T-cells | Standard Deviation 76.9 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 2 | 49.11 CD4+ T-cells/million T-cells | Standard Deviation 83.84 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 6 | 66.67 CD4+ T-cells/million T-cells | Standard Deviation 64.44 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Day 0 | 158.56 CD4+ T-cells/million T-cells | Standard Deviation 363.46 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 6 | 53.78 CD4+ T-cells/million T-cells | Standard Deviation 53.78 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 6 | 46.67 CD4+ T-cells/million T-cells | Standard Deviation 61.07 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 12 | 60.50 CD4+ T-cells/million T-cells | Standard Deviation 61.35 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 12 | 34.25 CD4+ T-cells/million T-cells | Standard Deviation 38.37 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 6 | 57.78 CD4+ T-cells/million T-cells | Standard Deviation 72.39 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Day 44 | 61.00 CD4+ T-cells/million T-cells | Standard Deviation 77.57 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Day 0 | 21.89 CD4+ T-cells/million T-cells | Standard Deviation 30.92 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 12 | 32.13 CD4+ T-cells/million T-cells | Standard Deviation 45.05 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Day 0 | 18.67 CD4+ T-cells/million T-cells | Standard Deviation 36.54 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 12 | 54.50 CD4+ T-cells/million T-cells | Standard Deviation 59.96 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 2 | 365.00 CD4+ T-cells/million T-cells | Standard Deviation 729.94 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Day 0 | 46.67 CD4+ T-cells/million T-cells | Standard Deviation 51.44 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 2 | 51.78 CD4+ T-cells/million T-cells | Standard Deviation 82.87 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Day 44 | 328.25 CD4+ T-cells/million T-cells | Standard Deviation 556.42 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Day 44 | 80.13 CD4+ T-cells/million T-cells | Standard Deviation 47.22 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 2 | 15.11 CD4+ T-cells/million T-cells | Standard Deviation 24.79 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 6 | 101.38 CD4+ T-cells/million T-cells | Standard Deviation 132.38 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 2 | 65.56 CD4+ T-cells/million T-cells | Standard Deviation 84.74 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Day 0 | 60.78 CD4+ T-cells/million T-cells | Standard Deviation 71.21 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 12 | 99.38 CD4+ T-cells/million T-cells | Standard Deviation 106.52 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 2 | 145.56 CD4+ T-cells/million T-cells | Standard Deviation 179.74 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 2 | 69.89 CD4+ T-cells/million T-cells | Standard Deviation 143.34 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Day 44 | 104.22 CD4+ T-cells/million T-cells | Standard Deviation 146.67 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Day 44 | 87.11 CD4+ T-cells/million T-cells | Standard Deviation 64.23 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Day 0 | 30.00 CD4+ T-cells/million T-cells | Standard Deviation 57.59 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 2 | 261.78 CD4+ T-cells/million T-cells | Standard Deviation 385.82 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 6 | 83.75 CD4+ T-cells/million T-cells | Standard Deviation 122.43 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 6 | 140.75 CD4+ T-cells/million T-cells | Standard Deviation 210.46 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Day 44 | 311.00 CD4+ T-cells/million T-cells | Standard Deviation 352.09 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 12 | 45.63 CD4+ T-cells/million T-cells | Standard Deviation 50.45 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 12 | 101.25 CD4+ T-cells/million T-cells | Standard Deviation 197.89 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Day 0 | 46.56 CD4+ T-cells/million T-cells | Standard Deviation 78.36 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 12 | 74.00 CD4+ T-cells/million T-cells | Standard Deviation 77.45 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Day 44 | 243.00 CD4+ T-cells/million T-cells | Standard Deviation 441.48 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Day 0 | 5.56 CD4+ T-cells/million T-cells | Standard Deviation 10.45 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 6 | 29.75 CD4+ T-cells/million T-cells | Standard Deviation 46.2 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 6 | 73.75 CD4+ T-cells/million T-cells | Standard Deviation 55.65 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Day 0 | 157.56 CD4+ T-cells/million T-cells | Standard Deviation 206.05 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 2 | 99.78 CD4+ T-cells/million T-cells | Standard Deviation 123.76 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Day 44 | 138.44 CD4+ T-cells/million T-cells | Standard Deviation 123.44 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 6 | 103.88 CD4+ T-cells/million T-cells | Standard Deviation 165.37 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 2 | 23.00 CD4+ T-cells/million T-cells | Standard Deviation 30.72 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Day 0 | 30.44 CD4+ T-cells/million T-cells | Standard Deviation 63.9 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 6 | 94.13 CD4+ T-cells/million T-cells | Standard Deviation 112.3 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 2 | 283.56 CD4+ T-cells/million T-cells | Standard Deviation 380.4 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 12 | 31.00 CD4+ T-cells/million T-cells | Standard Deviation 36.44 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 12 | 132.33 CD4+ T-cells/million T-cells | Standard Deviation 216.98 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Day 44 | 297.78 CD4+ T-cells/million T-cells | Standard Deviation 368.77 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Day 0 | 93.56 CD4+ T-cells/million T-cells | Standard Deviation 155.14 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Day 44 | 161.56 CD4+ T-cells/million T-cells | Standard Deviation 161.44 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Day 0 | 47.22 CD4+ T-cells/million T-cells | Standard Deviation 44.13 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 2 | 121.89 CD4+ T-cells/million T-cells | Standard Deviation 152.43 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 12 | 50.44 CD4+ T-cells/million T-cells | Standard Deviation 54.97 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 6 | 143.63 CD4+ T-cells/million T-cells | Standard Deviation 130.22 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Day 44 | 69.67 CD4+ T-cells/million T-cells | Standard Deviation 84.3 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 12 | 101.78 CD4+ T-cells/million T-cells | Standard Deviation 108.18 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 2 | 1470.00 CD4+ T-cells/million T-cells | Standard Deviation 1160.99 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Day 0 | 23.58 CD4+ T-cells/million T-cells | Standard Deviation 34.72 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Day 44 | 1937.11 CD4+ T-cells/million T-cells | Standard Deviation 1457.55 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 2 | 1308.50 CD4+ T-cells/million T-cells | Standard Deviation 1000.94 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 6 | 791.54 CD4+ T-cells/million T-cells | Standard Deviation 636.43 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 12 | 784.57 CD4+ T-cells/million T-cells | Standard Deviation 613.62 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Day 0 | 60.05 CD4+ T-cells/million T-cells | Standard Deviation 67.01 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Day 44 | 3536.04 CD4+ T-cells/million T-cells | Standard Deviation 1850.1 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 2 | 2429.89 CD4+ T-cells/million T-cells | Standard Deviation 1309.28 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 6 | 1320.63 CD4+ T-cells/million T-cells | Standard Deviation 1002.27 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 12 | 1282.00 CD4+ T-cells/million T-cells | Standard Deviation 819.01 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Day 0 | 52.74 CD4+ T-cells/million T-cells | Standard Deviation 64.54 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Day 44 | 2133.76 CD4+ T-cells/million T-cells | Standard Deviation 1825.49 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 6 | 906.78 CD4+ T-cells/million T-cells | Standard Deviation 935.03 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 12 | 786.23 CD4+ T-cells/million T-cells | Standard Deviation 803.67 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Day 0 | 107.84 CD4+ T-cells/million T-cells | Standard Deviation 225.52 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Day 44 | 7843.87 CD4+ T-cells/million T-cells | Standard Deviation 4284.29 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 2 | 5291.91 CD4+ T-cells/million T-cells | Standard Deviation 2921.62 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 6 | 3157.02 CD4+ T-cells/million T-cells | Standard Deviation 2345.2 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 12 | 2965.34 CD4+ T-cells/million T-cells | Standard Deviation 2148.86 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 12 | 766.55 CD4+ T-cells/million T-cells | Standard Deviation 549.94 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 6 | 574.18 CD4+ T-cells/million T-cells | Standard Deviation 536.34 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 6 | 775.63 CD4+ T-cells/million T-cells | Standard Deviation 588.91 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Day 44 | 777.68 CD4+ T-cells/million T-cells | Standard Deviation 662.55 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 12 | 432.85 CD4+ T-cells/million T-cells | Standard Deviation 379.08 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 2 | 1306.25 CD4+ T-cells/million T-cells | Standard Deviation 1320.29 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Day 44 | 1662.85 CD4+ T-cells/million T-cells | Standard Deviation 1462.02 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Day 0 | 81.00 CD4+ T-cells/million T-cells | Standard Deviation 143.07 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Day 0 | 77.98 CD4+ T-cells/million T-cells | Standard Deviation 87.63 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Day 0 | 32.75 CD4+ T-cells/million T-cells | Standard Deviation 62.91 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Day 44 | 3231.88 CD4+ T-cells/million T-cells | Standard Deviation 2077.15 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 12 | 374.65 CD4+ T-cells/million T-cells | Standard Deviation 319.92 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 6 | 411.95 CD4+ T-cells/million T-cells | Standard Deviation 290.81 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 2 | 2575.98 CD4+ T-cells/million T-cells | Standard Deviation 1972.59 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 2 | 562.63 CD4+ T-cells/million T-cells | Standard Deviation 473.95 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 12 | 1433.63 CD4+ T-cells/million T-cells | Standard Deviation 1020.8 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 6 | 1539.85 CD4+ T-cells/million T-cells | Standard Deviation 1100.27 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Day 44 | 1039.80 CD4+ T-cells/million T-cells | Standard Deviation 830.73 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 2 | 751.35 CD4+ T-cells/million T-cells | Standard Deviation 521.38 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Day 0 | 60.70 CD4+ T-cells/million T-cells | Standard Deviation 91.26 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Day 44 | 850.86 CD4+ T-cells/million T-cells | Standard Deviation 724.32 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 6 | 1198.74 CD4+ T-cells/million T-cells | Standard Deviation 748.47 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Day 44 | 3041.74 CD4+ T-cells/million T-cells | Standard Deviation 1961.13 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 6 | 435.71 CD4+ T-cells/million T-cells | Standard Deviation 293.58 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 6 | 562.26 CD4+ T-cells/million T-cells | Standard Deviation 402.53 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Day 0 | 80.51 CD4+ T-cells/million T-cells | Standard Deviation 126.89 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 2 | 1253.06 CD4+ T-cells/million T-cells | Standard Deviation 685.13 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 6 | 398.62 CD4+ T-cells/million T-cells | Standard Deviation 348.32 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Month 12 | 718.17 CD4+ T-cells/million T-cells | Standard Deviation 533.47 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 12 | 485.23 CD4+ T-cells/million T-cells | Standard Deviation 478.78 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 12 | 1347.26 CD4+ T-cells/million T-cells | Standard Deviation 988.06 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Day 44 | 1661.03 CD4+ T-cells/million T-cells | Standard Deviation 1108.49 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Day 44 | 1034.77 CD4+ T-cells/million T-cells | Standard Deviation 836.85 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Day 0 | 39.80 CD4+ T-cells/million T-cells | Standard Deviation 65.83 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Month 2 | 2471.94 CD4+ T-cells/million T-cells | Standard Deviation 1509.43 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | RT, Day 0 | 148.37 CD4+ T-cells/million T-cells | Standard Deviation 346.73 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p24, Day 0 | 68.31 CD4+ T-cells/million T-cells | Standard Deviation 100 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 2 | 682.70 CD4+ T-cells/million T-cells | Standard Deviation 553.88 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | p17, Month 12 | 501.60 CD4+ T-cells/million T-cells | Standard Deviation 451.23 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers | Nef, Month 2 | 826.45 CD4+ T-cells/million T-cells | Standard Deviation 539.88 |
Secondary
Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker
Antigen-specific CD4+ T-cells can express CD40 ligand (CD40-L) and produce the cytokines Interleukin 2 (IL-2) and/or Tumor Necrosis Factor alpha (TNF-α) and/or Interferon-gamma (IFN-γ). Frequency of CD4+ T-cells expressing markers in response to the F4co fusion protein (all antigens) was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (p17, p24, Nef, RT). Results are presented as determined by Intracellular Cytokine Staining (ICS).
Time frame: At Month 0, Day 44, Month 2, Month 6 and Month 12
Population: Analysis was performed on the According-to-Protocol cohort for Immunogenicity that included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with procedures and intervals defined in protocol, with no elimination criteria during study) for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 2 | 31.56 CD4+ T-cells/million T-cells | Standard Deviation 58.84 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 6 | 46.67 CD4+ T-cells/million T-cells | Standard Deviation 70.3 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Day 0 | 25.78 CD4+ T-cells/million T-cells | Standard Deviation 45.94 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Day 44 | 58.25 CD4+ T-cells/million T-cells | Standard Deviation 67.23 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Day 44 | 52.63 CD4+ T-cells/million T-cells | Standard Deviation 65.28 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 2 | 30.56 CD4+ T-cells/million T-cells | Standard Deviation 55.59 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 2 | 17.33 CD4+ T-cells/million T-cells | Standard Deviation 28.18 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 6 | 46.67 CD4+ T-cells/million T-cells | Standard Deviation 61.07 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 6 | 22.22 CD4+ T-cells/million T-cells | Standard Deviation 28.83 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 12 | 28.50 CD4+ T-cells/million T-cells | Standard Deviation 42.64 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Day 0 | 32.56 CD4+ T-cells/million T-cells | Standard Deviation 46.31 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 2 | 109.22 CD4+ T-cells/million T-cells | Standard Deviation 67.04 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Day 0 | 51.67 CD4+ T-cells/million T-cells | Standard Deviation 55.49 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Day 44 | 107.75 CD4+ T-cells/million T-cells | Standard Deviation 115.2 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Day 44 | 47.25 CD4+ T-cells/million T-cells | Standard Deviation 38.39 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Day 0 | 77.44 CD4+ T-cells/million T-cells | Standard Deviation 83.84 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 6 | 53.78 CD4+ T-cells/million T-cells | Standard Deviation 85.56 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 12 | 23.00 CD4+ T-cells/million T-cells | Standard Deviation 36.26 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 12 | 34.25 CD4+ T-cells/million T-cells | Standard Deviation 38.37 |
| SB732461 Non-adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 12 | 54.50 CD4+ T-cells/million T-cells | Standard Deviation 59.96 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Day 44 | 205.22 CD4+ T-cells/million T-cells | Standard Deviation 375.13 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 2 | 242.22 CD4+ T-cells/million T-cells | Standard Deviation 349.31 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 6 | 83.75 CD4+ T-cells/million T-cells | Standard Deviation 122.43 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Day 0 | 22.00 CD4+ T-cells/million T-cells | Standard Deviation 40.81 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Day 44 | 250.00 CD4+ T-cells/million T-cells | Standard Deviation 351.18 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Day 0 | 31.67 CD4+ T-cells/million T-cells | Standard Deviation 44.13 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 12 | 20.75 CD4+ T-cells/million T-cells | Standard Deviation 47.65 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 2 | 75.67 CD4+ T-cells/million T-cells | Standard Deviation 104.05 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Day 0 | 27.56 CD4+ T-cells/million T-cells | Standard Deviation 48.52 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Day 44 | 89.00 CD4+ T-cells/million T-cells | Standard Deviation 81.17 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 12 | 70.13 CD4+ T-cells/million T-cells | Standard Deviation 140.5 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Day 44 | 102.00 CD4+ T-cells/million T-cells | Standard Deviation 171.17 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 6 | 36.25 CD4+ T-cells/million T-cells | Standard Deviation 56.89 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Day 0 | 16.78 CD4+ T-cells/million T-cells | Standard Deviation 16.08 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 2 | 142.67 CD4+ T-cells/million T-cells | Standard Deviation 138.05 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 12 | 99.38 CD4+ T-cells/million T-cells | Standard Deviation 106.52 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 6 | 140.75 CD4+ T-cells/million T-cells | Standard Deviation 210.46 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 6 | 80.50 CD4+ T-cells/million T-cells | Standard Deviation 119.81 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 2 | 60.11 CD4+ T-cells/million T-cells | Standard Deviation 79.9 |
| SB732461 Non-adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 12 | 74.00 CD4+ T-cells/million T-cells | Standard Deviation 77.45 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 2 | 30.22 CD4+ T-cells/million T-cells | Standard Deviation 40.38 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 12 | 42.56 CD4+ T-cells/million T-cells | Standard Deviation 66.95 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 6 | 61.63 CD4+ T-cells/million T-cells | Standard Deviation 74.83 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Day 44 | 262.00 CD4+ T-cells/million T-cells | Standard Deviation 327.68 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 2 | 209.89 CD4+ T-cells/million T-cells | Standard Deviation 363.37 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 12 | 25.00 CD4+ T-cells/million T-cells | Standard Deviation 28.14 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 12 | 101.78 CD4+ T-cells/million T-cells | Standard Deviation 108.18 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 6 | 143.63 CD4+ T-cells/million T-cells | Standard Deviation 130.22 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Day 0 | 29.11 CD4+ T-cells/million T-cells | Standard Deviation 43.11 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Day 0 | 21.33 CD4+ T-cells/million T-cells | Standard Deviation 27.16 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Day 44 | 119.22 CD4+ T-cells/million T-cells | Standard Deviation 160.14 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Day 0 | 7.89 CD4+ T-cells/million T-cells | Standard Deviation 10.86 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Day 0 | 78.11 CD4+ T-cells/million T-cells | Standard Deviation 98.18 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 2 | 73.00 CD4+ T-cells/million T-cells | Standard Deviation 93.1 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 6 | 38.75 CD4+ T-cells/million T-cells | Standard Deviation 40.15 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Day 44 | 108.22 CD4+ T-cells/million T-cells | Standard Deviation 97.17 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Day 44 | 57.22 CD4+ T-cells/million T-cells | Standard Deviation 76.97 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 6 | 103.88 CD4+ T-cells/million T-cells | Standard Deviation 165.37 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 2 | 87.22 CD4+ T-cells/million T-cells | Standard Deviation 83.82 |
| SB732461 Non-adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 12 | 132.33 CD4+ T-cells/million T-cells | Standard Deviation 216.98 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 12 | 722.80 CD4+ T-cells/million T-cells | Standard Deviation 780.58 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Day 0 | 17.95 CD4+ T-cells/million T-cells | Standard Deviation 25.64 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Day 44 | 1724.07 CD4+ T-cells/million T-cells | Standard Deviation 1335.8 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 2 | 1238.82 CD4+ T-cells/million T-cells | Standard Deviation 968.59 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 6 | 762.59 CD4+ T-cells/million T-cells | Standard Deviation 608.13 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 12 | 766.55 CD4+ T-cells/million T-cells | Standard Deviation 620.56 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Day 0 | 30.60 CD4+ T-cells/million T-cells | Standard Deviation 41.68 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Day 44 | 3078.59 CD4+ T-cells/million T-cells | Standard Deviation 1694.26 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 2 | 2228.00 CD4+ T-cells/million T-cells | Standard Deviation 1255.4 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 6 | 1320.63 CD4+ T-cells/million T-cells | Standard Deviation 1002.27 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 12 | 1282.00 CD4+ T-cells/million T-cells | Standard Deviation 819.01 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Day 0 | 40.02 CD4+ T-cells/million T-cells | Standard Deviation 49.98 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Day 44 | 1822.50 CD4+ T-cells/million T-cells | Standard Deviation 1553.8 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 2 | 1307.89 CD4+ T-cells/million T-cells | Standard Deviation 1080.1 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 6 | 855.13 CD4+ T-cells/million T-cells | Standard Deviation 901.48 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Day 0 | 52.53 CD4+ T-cells/million T-cells | Standard Deviation 109.33 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Day 44 | 6760.11 CD4+ T-cells/million T-cells | Standard Deviation 3832.3 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 2 | 4731.64 CD4+ T-cells/million T-cells | Standard Deviation 2761.73 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 6 | 3157.02 CD4+ T-cells/million T-cells | Standard Deviation 2345.2 |
| SB732461 adjuvanted_LD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 12 | 2965.34 CD4+ T-cells/million T-cells | Standard Deviation 2148.86 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Day 44 | 2787.43 CD4+ T-cells/million T-cells | Standard Deviation 1785.69 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 12 | 404.98 CD4+ T-cells/million T-cells | Standard Deviation 364.64 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 12 | 345.55 CD4+ T-cells/million T-cells | Standard Deviation 320.76 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 12 | 766.55 CD4+ T-cells/million T-cells | Standard Deviation 549.94 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 6 | 376.80 CD4+ T-cells/million T-cells | Standard Deviation 291.36 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Day 44 | 1441.93 CD4+ T-cells/million T-cells | Standard Deviation 1286.57 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 2 | 2304.75 CD4+ T-cells/million T-cells | Standard Deviation 1798 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 6 | 775.63 CD4+ T-cells/million T-cells | Standard Deviation 588.91 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Day 0 | 21.90 CD4+ T-cells/million T-cells | Standard Deviation 44.84 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Day 0 | 52.85 CD4+ T-cells/million T-cells | Standard Deviation 96.57 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Day 44 | 696.78 CD4+ T-cells/million T-cells | Standard Deviation 592.73 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 12 | 1433.63 CD4+ T-cells/million T-cells | Standard Deviation 1020.8 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 6 | 1539.85 CD4+ T-cells/million T-cells | Standard Deviation 1100.27 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 6 | 532.80 CD4+ T-cells/million T-cells | Standard Deviation 508.78 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Day 44 | 872.83 CD4+ T-cells/million T-cells | Standard Deviation 706 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Day 0 | 54.95 CD4+ T-cells/million T-cells | Standard Deviation 68.53 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Day 0 | 39.53 CD4+ T-cells/million T-cells | Standard Deviation 59.12 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 2 | 1171.50 CD4+ T-cells/million T-cells | Standard Deviation 1220.16 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 2 | 678.78 CD4+ T-cells/million T-cells | Standard Deviation 503.13 |
| SB732461 adjuvanted_MD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 2 | 517.38 CD4+ T-cells/million T-cells | Standard Deviation 440.05 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 2 | 713.33 CD4+ T-cells/million T-cells | Standard Deviation 490.14 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 6 | 562.26 CD4+ T-cells/million T-cells | Standard Deviation 402.53 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Day 0 | 30.60 CD4+ T-cells/million T-cells | Standard Deviation 49.28 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 6 | 374.32 CD4+ T-cells/million T-cells | Standard Deviation 302.71 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 2 | 1120.58 CD4+ T-cells/million T-cells | Standard Deviation 654.53 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Day 44 | 1446.17 CD4+ T-cells/million T-cells | Standard Deviation 990.24 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Day 0 | 52.14 CD4+ T-cells/million T-cells | Standard Deviation 80.65 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Day 0 | 63.80 CD4+ T-cells/million T-cells | Standard Deviation 74.44 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 12 | 462.29 CD4+ T-cells/million T-cells | Standard Deviation 439.06 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Month 12 | 426.34 CD4+ T-cells/million T-cells | Standard Deviation 447.54 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Day 44 | 2518.71 CD4+ T-cells/million T-cells | Standard Deviation 1389.15 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 6 | 360.32 CD4+ T-cells/million T-cells | Standard Deviation 324.15 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 12 | 1347.26 CD4+ T-cells/million T-cells | Standard Deviation 988.06 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 2 | 2107.61 CD4+ T-cells/million T-cells | Standard Deviation 1107.18 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Month 2 | 625.88 CD4+ T-cells/million T-cells | Standard Deviation 525.66 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p17, Day 44 | 740.91 CD4+ T-cells/million T-cells | Standard Deviation 637.48 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Day 44 | 862.20 CD4+ T-cells/million T-cells | Standard Deviation 721.64 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | Nef, Day 0 | 58.97 CD4+ T-cells/million T-cells | Standard Deviation 101.11 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | RT, Month 6 | 1198.74 CD4+ T-cells/million T-cells | Standard Deviation 748.47 |
| SB732461 adjuvanted_HD Group | Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker | p24, Month 12 | 718.17 CD4+ T-cells/million T-cells | Standard Deviation 533.47 |